Navigation Links
VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
Date:9/1/2011

MOUNTAIN VIEW, Calif., Sept. 1, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for its investigational drug candidate, avanafil, for the treatment of erectile dysfunction (ED). The target date for the FDA to complete its review of the avanafil NDA is April 29, 2012. In previously announced results from the pivotal phase 3 trials, patients treated with avanafil achieved significant improvement in erectile function compared to placebo. The avanafil development program included over 1,350 patients and avanafil was shown to be well tolerated and effective in treating patients with general ED and diabetics with ED. The long-term safety study also confirmed the results observed in the phase 3 studies.

"We are pleased with FDA's acceptance of our NDA. If approved, avanafil could be a valuable treatment alternative for the 18 million men in the United States that suffer from ED," stated Peter Y. Tam, president of VIVUS.

About AvanafilAvanafil is an investigational oral medication being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL,
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
2. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
3. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
4. VIVUS to Present at Three Upcoming Investor Conferences in March
5. VIVUS Provides Regulatory Update on QNEXA NDA
6. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
7. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
10. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
11. VIVUS Announces Sale of MUSE Assets to Meda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... trial of  VAL-083  (dianhydrogalactitol) in patients with refractory ... form of human brain cancer. Results ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... Clinical Development for the Treatment of ... Opioid Bowel Dysfunction, ... presented positive results this week from Phase,1 and preclinical studies of ... in Las Vegas, Nevada. NKTR-118 is,Nektar,s proprietary oral therapy being studied ...
... physician leading clinical trials, FREEPORT, N.Y., ... in treating facial bruising from injectable cosmetic,treatments ... known for,treating under-eye circles. Pinoxide is ... (BMTd),created by AGI Dermatics and formulated in ...
Cached Medicine Technology:Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 2Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 3Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 5Promising Results in Treating Facial Bruising From Injectables 2
(Date:6/1/2015)... Carson Energy also announced they have ... transactions. AdvantaIRA Trust, LLC is the country’s largest self-directed ... fund positions using IRA’s does 2 things:, 1. It ... even if there current cash position will not allow ... for Carson and their investors to be able to ...
(Date:6/1/2015)... 01, 2015 The federal court overseeing ... amended the Case Management Order governing case selection for ... Amended Order which was issued in the U.S. ... 2015, directs the parties to submit a Proposed Case ... that outlines parameters and the process for selecting AbbVie-only ...
(Date:6/1/2015)... June 01, 2015 Atagi Plastic Surgery ... been named an Ultherapy® Ultra Treatment Provider ... and Skin Aesthetics is one of only six practices ... premier treatment provider. , Atagi Plastic Surgery and ... Denver area has led the practice to earn the ...
(Date:6/1/2015)... Washington, D.C. (PRWEB) June 01, 2015 Linda ... tired and had an irregular heartbeat. At first she thought ... soon found out it was much more than that. After ... valve disease. Linda admitted she felt afraid about what might ... as five million Americans are diagnosed with valve disease each ...
(Date:6/1/2015)... June 01, 2015 On May 14, ... center hosted the Cherry Creek Chamber of Commerce ... clinic. Urgent care centers typically do not offer primary ... AFC/Doctors Express Cherry Creek Urgent Care staff to schedule ... , From 5:30 to 7:30 p.m. the center hosted ...
Breaking Medicine News(10 mins):Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2
... of Michigan scientists have found that a deficiency in a key ... type of adult brain cancer. The study, conducted in mice that ... and a way to screen for the disease early. Appearing ... in mice show for the first time that:, Glioblastoma, the ...
... A closer look at regulatory and clinical concerns with ... to an educational advisory by the International Society for ... issue of The Journal of Heart and Lung ... Thoracic transplant patients ...
... Georgia to use a new, cutting edge diagnostic ... outcomes. , , WOBURN, Mass., and VEDBAEK, Denmark, ... Medical Center in Savannah, Georgia has implemented AdvanDx,s PNA FISH(R) ... than conventional methods to help their physicians, pharmacists and nurses ...
... addresses limitations of current randomized trials , , ... Inc . highlighted recent clinical panel presentations underscoring ... for treating asthma in adults and children. The company ... to mixed results in some randomized trials of eNO-guided ...
... Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced ... has approved the design of pivotal, Phase 2b/3 clinical ... drug for the acute treatment of patients with paroxysmal ... process. , , ATPace(TM) is a novel ...
... China, June 2 /PRNewswire-Asia/ -- China Nepstar Chain Drugstore,Ltd. ... "Company"), the largest drugstore,chain in China based on the ... Mr. Jason (Xinghua) Wu as the Chief Operating,Officer. ... overseeing,procurement, logistics, store development and store operations. He ...
Cached Medicine News:Health News:Most common brain cancer may start in neural stem cells 2Health News:Most common brain cancer may start in neural stem cells 3Health News:Most common brain cancer may start in neural stem cells 4Health News:More stringent evaluation on the use of generic medications in thoracic transplantation 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Clinical Utility of Exhaled Nitric Oxide Highlighted By American Thoracic Society Panel 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 3Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 4Health News:China Nepstar Chain Drugstore Appoints Chief Operating Officer 2Health News:China Nepstar Chain Drugstore Appoints Chief Operating Officer 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: